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Introduction
The outcome of children with juvenile idiopathic arthritis
(JIA) has improved over the last decades. However, the
disease course is still not easy to predict, especially based
on traditional clinical factors. In the German prospective
controlled observational multicentre study ICON-JIA
(Inception Cohort Of Newly-diagnosed patients with JIA)
patients with diagnosis of JIA <12 months are included
for long-term observation to improve the prediction and
understanding of JIA outcomes.
Objectives
To analyse biomarkers (collected in the early phase (0-3
months) that may predict inactive disease within 12 months
in JIA patients treated in specialized centres.
Methods
ICON comprised an assessment by patients and parents
via standardized questionnaires and clinical examinations
by paediatric rheumatologists. Sera were collected from
191 children (132 girls, 59 boys), with JIA diagnosis based
on the ILAR classification with a median age of 5 years
(range = 1 to 17). At inclusion into the study, the disease
duration since diagnosis was less than 6 months. All sera
collected at inclusion and after 3 months were tested for
biomarkers MRP8/14 and S100A12. Furthermore, 68 sera
collected at inclusion were also assayed for CRP and ESR
as well as the cytokines IL-12p70, IFN-gamma, IL-17A,
IL-2, IL-10, IL-9, IL-22, IL-6, IL-13, IL-4, IL-5, IL-1 beta,
and TNF-alpha.
Results
After a 12 months follow-up, 106 children were diagnosed
with inactive and 85 children with active disease. Of the
biomarkers measured in sera collected at inclusion, only a
higher ESR at baseline (median 27 vs. 19 mm/h, p =
0.013) was significantly associated with a persistently
active disease at 12 months follow-up. While none of the
cytokine levels revealed significant differences, both
MRP8/14 (median 1,145 vs. 815 ng/ml, p = 0.041) and
S100A12 levels (120 vs. 87 ng/ml, p = 0.032) in sera col-
lected after 3 months of specialized care were significantly
higher in patients who did not reach inactive disease status
after 12 months. ROC analyses for MRP8/14 (area under
curve, AUC 0.618, 95% CI 0.510-0.726, p = 0.041) and for
S100A12 (AUC 0.651, 95% CI 0.514-0.717, p = 0.033)
revealed a moderate but robust predictive power of these
biomarkers.
Conclusion
Markers of inflammation may help to assess the probabil-
ity to achieve inactive disease within 12 months of specia-
lised care in patients with early JIA. Markers of innate
immune activation, S100A12 and MRP8/14, analysed
after three months of specialized care, may potentially
predict whether patients will reach inactive disease within
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